| Code | CSB-RA016023MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to REGN-5381, designed to target NPR1 (natriuretic peptide receptor 1), also known as NPR-A or guanylyl cyclase-A. NPR1 functions as a transmembrane receptor that binds atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), playing a crucial role in cardiovascular homeostasis through regulation of blood pressure, sodium balance, and fluid volume. Upon ligand binding, NPR1 catalyzes the production of cyclic GMP, initiating signaling cascades that promote vasodilation, natriuresis, and inhibition of the renin-angiotensin-aldosterone system. Dysregulation of NPR1 signaling is implicated in hypertension, heart failure, and various cardiovascular disorders.
REGN-5381 represents a therapeutic antibody developed for investigation in cardiovascular disease research. This biosimilar provides researchers with a valuable tool for studying NPR1 biology, natriuretic peptide signaling pathways, and cardiovascular physiology. It enables investigation of receptor function, ligand-receptor interactions, and the therapeutic potential of modulating NPR1 activity in disease models.
There are currently no reviews for this product.